Committee Approval Date:
Publishing Lead:
Scott M. Robertson scott.m.robertson@kp.org
Contributing or Reviewing Work Groups:
Pharmacy WG
Structured Documents WG
FHIR Development Project Insight ID:
1743
revision of project from a guidance document to FHIR IG is in progress
Scope of coverage:
This IG will address pharmacist- and pharmacy-specific requirements and terminologies relative to the C-CDA on FHIR IG, specifically the Consultation Note. This IG will also provide information on the C-CDA version of Pharmacist Consultant Note including mapping between the C-CDA and FHIR presentation. This IG builds upon an existing NCPDP Consultant Pharmacist Consult Note Guidance Document, specifically to add FHIR as an optional (or preferred) implementation. This is a joint NCPDP/HL7 project to publish under joint copyright.
Content location:
https://github.com/HL7/pharm-consult-note
Proposed IG Title:
Pharmacists Consultation Note IG
Proposed IG realm and code:
us/pharm-consult-note
FHIR Core version(s):
R4, since C-CDA on FHIR IG STU 1.1 is based on R4
Maintenance Plan:
Joint maintenance between HL7 Pharmacy WG and NCPDP WG14 Long Term Post Acute Care (LTPAC) Clinical Pharmacist Interoperability Task Group.
Short Description:
This IG provides pharmacist- and pharmacy-specific guidance and requirements for the use of C-CDA on FHIR IG (STU 1.1) Consultation Note for a Pharmacist Consultation Note. This addresses sections that are required or recommended for a Pharmacist Consultation Note, which may differ from C-CDA on FHIR IG and US Core. Identifies required or recommended code sets/value sets for pharmacy use cases.
Long Description:
The Pharmacist Consultation Note IG provides requirements and recommendations for using C-CDA on FHIR IG (STU 1.1) Consultation Note in pharmacy use cases. The audience for this IG are system vendors, especially pharmacy system vendors, where the system/application supports pharmacists with medication review and other consulting services. Examples include: a pharmacist's medication regimen review for LTPAC patients; reporting of evaluations performed in a pharmacist-run clinic; and a pharmacist responding to a provider-requested review and recommendations for a patient's medications relative to their conditions, allergies, etc.
This IG also provides guidance on the use of C-CDA R2.1 for Pharmacist Consultation Notes. At the present time, C-CDA documents are widely used and previous guidance described C-CDA implementation for consulting pharmacists. This IG updates that prior guidance and includes material to facilitate the Pharmacist Consultation Note transition from C-CDA to FHIR (C-CDA on FHIR IG).
Involved parties:
NCPDP
Pharmacy HIT Collaborative
National Community Pharmacists Association (NCPA) Innovation Center
American Society of Clinical Pharmacists (ASCP)
Expected implementations:
in discussion with
Content sources:
Requirements from subject matter experts in NCPDP, TabulaRasa, GeriMed, ASCP, PharmHIT
Example Scenarios:
CMS-required Pharmacist Medication Regimen Review (MRR) for patients in Long Term and Post-Acute Care (LTPAC) facilities.
Provider-requested Pharmacist assessment of a patient's current medications. Common request in LTPAC and integrated medical systems.
IG Relationships:
dependent on C-CDA on FHIR IG 1.1.0 - (FHIR R4) STU Release 1.1 and its dependencies
no expected dependencies on this IG
Timelines:
Sept 2022 ballot